Fig. 3. Effects of Noggin on epithelial survival. (A) Brightfield and (B) fluorescence view of a Noggin-treated embryo showing a decrease in Acridine Orange staining near the bead (arrowheads). (C) Treated and (D) control sides of the frontonasal mass showing an increased thickness in the epithelium (arrow in C, stage 26). (E) Decrease in expression in epithelium and mesenchyme six hours after the first set of beads (arrow, stage 22+). (F) Increase in size and intensity of expression domain near bead (arrow), 12 hours after second set of beads, stage 28. (G) No change in Shh expression 12 hours after the first set of beads were applied (stage 24, arrow). (H) Increase in Shh expression in the epithelium (arrowheads) of the globular process (upper arrow) and of the anterior-medial maxillary prominence (stage 29). On the contralateral side there is no expression of Shh in the globular process or in the anterior-medial maxillary prominence (lower arrow). Scale bars: 0.5 mm for A,B,E-H; 100 µm for C,D. Abbreviations: b, bead; fnm, frontonasal mass; mx, maxillary prominence.

Return to article